The thymus produces precursors of both effectors and regulatory T cells (Tconv and Treg, respectively) whose interactions prevents autoimmunity while allowing efficient protective immune responses. Tumors express a composite of self-and tumor-specific antigens and engage both Tconv and Treg cells. Along the aging process, the thymus involutes, and tumor incidence increases, a correlation proposed previously to be causal and the result of effector cell decline. In this work, we directly tested whether interruption of thymic activity in adult mice affects Foxp3 expressing Treg composition and function, and alters tumor immune surveillance. Young adult mice, on two different genetic backgrounds, were surgically thymectomized (TxT) and analyzed or challenged 2 months later. Cellular analysis revealed a 10-fold decrease in both Tconv and Treg numbers and a bias for activated cells. The persisting Treg displayed reduced stability of Foxp3 expression and, as a population, showed compromised return to homeostasis upon induced perturbations. We next tested the growth of three tumor models from different origin and presenting distinct degrees of spontaneous immunogenicity. In none of these conditions adult TxT facilitated tumor growth. Rather TxT enhanced the efficacy of anti-tumor immunotherapies targeting Treg and/or the checkpoint CTLA4, as evidenced by increased frequency of responder mice and decreased intra-tumoral Treg to CD8 + IFNg + cell ratio. Together, our findings point to a scenario where abrogation of thymic activities affects preferentially the regulatory over the ridding arm of the immune activities elicited by tumors, and argues that higher incidence of tumors with age cannot be solely attributed to thymic output decline.
Introduction
The thymus exports T cells that colonize peripheral lymphoid and non-lymphoid organs and continuously replace dying T cells, ensuring the maintenance of a diverse reactive repertoire.
Thymic atrophy in response to various biological stresses, and involution with age, leads to alteration in peripheral T cell composition. T cells can be subdivided in two broad types, those "conventional" or effector cells, participating in the ridding functions of the immune system, and those endowed with regulatory functions, which maintain at check effector cells, and most notably prevent deleterious autoimmunity. The major subset of regulatory T cells (Treg) expresses the master transcription factor Foxp3, whose mutation leads to severe, lethal multiorgan autoimmunity in mice and humans (1-3). Several experimental and theoretical works have attempted to formalize which mechanisms ensure the adequate balance between regulatory and effector T cells number and composition in health. Overall the two cell subsets share only few TCR sequences when analyzed at the nucleotide level (4) , and the most consensual model remains that they must be docking on the same antigen presenting cells for regulation to occur and be reinforced (5) .
Most analyses on the impact on health of thymic surgical ablation, physiological atrophy or involution, focused on the ensuing restricted repertoire of effector T cells, which satisfyingly explains a reduced efficiency in targeting infectious agents. However, thymic output is also required to replenish the pool of peripheral Treg, through both the production of Treg already differentiated in the thymus (tTreg) (2) and the production of immature T cells that are the preferential precursors of bona fide Treg differentiated in the periphery (6) (7) (8) .
Cancer immune surveillance involves both the regulatory and effector arms of the immune system (9) . Cancer cells are derived from tissues that in health are not targeted by the ridding function of the immune system as these are maintained at check by Treg, among other suppressor mechanisms. In turn, beneficial anti-tumor immune responses have similarities with autoimmunity, as illustrated by the emergence of autoimmune manifestations upon immunotherapies (10, 11) .
More recent advances in genome analysis has revealed that most tumors express neo-antigens, encoded by mutated genes. Tumors bearing mutator mutations accumulate multiple neoantigens, and appear the best responders to immune therapies (12) . Nevertheless, Treg interacting with tumor antigens are identifiable and these derive both from tTreg and pTreg (13, 14) .
In a recent publication, Palmer et al (15) argued that the increased incidence of cancer with age is not caused by gradual accumulation of mutations as commonly accepted, but rather by a decline in the immune system, that the authors attribute to a decline in thymic T cell output. In their mathematical model, all T cells are treated as effector cells. Given the evidence that the thymus produces precursors of both effectors and Treg, and that the outcome of an immune response is the result of effector and Treg interactions, predicting the impact of thymic output interruption on tumor immune surveillance is non-trivial.
In the present work, we directly tested whether interruption of thymic activity in adult mice affects Treg composition and function in the periphery. Mice were surgically thymectomized (TxT) between 5 and 6 weeks of age to abrogate thymic output, and analyzed 2 months later. We first document that as for conventional T cells, Treg numbers decrease and the remaining cell population is biased for activated Treg. The persisting Treg are less stable and respond worse to induced homeostatic perturbations. We further tested the impact of adult TxT on the growth of three tumor models in two mouse strains of different genetic backgrounds. In none of the circumstances TxT facilitated tumor growth, and in some instances, TxT enhanced the efficacy of anti-tumor immunotherapies.
Results

Adult thymectomy alters both conventional and regulatory T cell composition.
We first analyzed the T cell composition in C57Bl/6 (B6) animals that had been submitted to adult thymectomy (TxT) or sham surgery (Sham) 2 months earlier ( Fig. 1A) . As expected, recent thymic emigrants identified as Qa-2 low were drastically decreased in TxT mice ( Fig. S1A) . Naïve CD4 and CD8 cells, as well as central memory Treg (cTreg) are identified as CD44 -CD62L + , while activated or effector memory CD4, CD8 and Treg (eTreg) cells are identified as CD44 + CD62L - (16) . Assessing both the frequency and absolute cell numbers revealed that the log decrease in cell numbers observed in TxT mice is mostly imputable to naïve T and cTreg cells, while the number of activated T and eTreg cells remains unaltered ( Fig. 1B, C) . Of note, when monitoring the cellular decline upon TxT in BALB/c (Ba) mice, the decrease in naïve CD4 or CD8 T cells and in cTreg numbers was much less marked and delayed, when compared to B6 animals (Fig. S1B) .
The extent of naïve T cell decline in B6 TxT mice was in the same range as in 15-month-old animals (Fig S1C) . TxT and Sham animals displayed similar frequency of Ki67+ cells in each T cell subset (Fig. S1D) , confirming peripheral proliferation does not compensate for cessation of thymic output in mice (17) . The frequency of activated cells that produced interferon-g (IFN-g) or tumor necrosis factor a (TNF-a) were not decreased in TxT mice when compared to Sham animals ( Fig. 1D) . We further sub-phenotyped Treg according to various markers ( Fig. 1E) .
Expression of Helios and Nrp1 has been proposed, and debated, as markers of Treg differentiated in the thymus (tTreg) versus in the periphery (pTreg) (18) . The frequency of cTreg expressing Nrp1 was increased in TxT mice, possibly indicating a lack of Nrp1 -pTreg, while Helios + cells were underrepresented. The intensity of Foxp3 expression in cTreg was slightly but significantly reduced in TxT animals, suggesting less robust stability or function. Analysis of other markers associated with Treg function, such as CD25, CTLA4 and TIGIT, revealed no significant differences between TxT and control mice, either for cTreg or eTreg. Together, these data indicate that interruption of thymic activity affects Treg composition in the periphery. 
Functional alteration of Treg upon adult thymectomy.
We next tested the function and stability of Treg isolated from TxT or Sham mice by adoptive transfer. Conventional CD4 and CD8 cells were purified from unmanipulated donors and injected alone or together with Treg in T cell deficient animals ( Fig. 2A) . In such adoptive transfer experiments conventional T cells expand vigorously and acquire an activated phenotype if injected alone, a process inhibited by the co-transfer of Treg. Treg isolated from TxT mice performed similarly to, or worse than Treg isolated from Sham mice, in controlling CD4 or CD8 cells, respectively. Adoptive transfer of Treg cells alone serves as an assay to test their plasticity/stability, measured through the frequency of cells that lose Foxp3 expression along the experiment. Tregs isolated from TxT mice, when compared to Sham donors, were less stable in this assay. Loss of Foxp3 expression in both types of Treg was equally prevented by co-transfer of CD4 cells, a mechanism shown before to involve IL-2 secreted by effector cells (19) , and not by co-transfer of CD8 cells. Adoptive transfer of conventional CD4 T cells alone serves also as an assay to measure differentiation of Treg in the periphery. Our previous work demonstrated that naïve cells isolated from TxT mice failed to express Foxp3 upon adoptive transfer into lymphodeficient mice (7) . We extended this finding by performing adoptive transfer into lymphoreplete animals. While donor cells and newly differentiated Treg are barely detectable in lymphoreplete recipients, these are readily measurable when using DEREG recipient animals partially deleted of endogenous Treg (8) . In the latter assay, as in lympho-deficient mice, cells isolated from TxT mice performed poorly ( Fig 2B) . Taken together, these data indicate that TxT mice bear compromised Treg that cannot be efficiently renewed through peripheral differentiation.
Altered return to homeostasis upon Treg depletion in thymectomized mice.
DEREG mice, which carry a BAC transgene covering the foxp3 locus knocked-in to encode DTR and GFP, offer a practical model to study Treg dynamics upon perturbation. Punctual injection of diphtheria toxin (DT), depletes all GFP + Treg in lymphoid and non-lymphoid tissues but spare DT resistant GFP -Treg that are Foxp3 + but do not express the BAC (Fig. S2A) . The rebound of Treg is rather fast and biphasic, with the rapid emergence (presumably expansion) of GFP-Treg followed by a slower reappearance (presumably de novo differentiation) of GFP + Treg (Fig. S2B ).
In this system GFP -Treg have been shown to be rather CD25 low , highly cycling, hyperactivated and exhausted (20) . By crossing DEREG mice with Foxp3 hCD2 animals bearing different congenic markers (CD45.2 and CD45.1, respectively), we produced a tool that allows functional analysis of GFP -Treg. Probing this system in adoptive transfer experiments revealed that hCD2 + GFPcells transferred into DT treated DEREG animals did not acquire GFP expression in a time frame during which endogenous GFP + cells had already emerged (Fig. S2C) . We also evidenced that the majority of Treg differentiated in the periphery upon adoptive transfer of Foxp3cells were GFP expressors ( Fig. S2D) . This analysis confirms that GFP -Treg in DEREG mice are not precursors of GFP + bona fide Treg, and are likely to represent aged Treg. 
Adult thymectomy does not prevent immune surveillance of tumor.
To directly test the functional outcome of adult thymectomy on tumor growth we first monitored the CT26 cell line. This colon carcinoma is not spontaneously immunogenic but sensitive to both Treg depletion and anti-CTLA4 therapies (21, 22) , making it an ideal model to test the impact of subtle immune alterations. CT26 tumor cells were implanted subcutaneously (s.c.) in the flank of syngeneic (Balb/c) alymphoid (RAG -/-), or wild type (WT) and DEREG mice, either TxT or Sham.
Due to the heterogeneous shapes of each tumor growth curve inside each experimental group, we relied on the modified individual tumor control index (iTCI) (23, 24) which informs on tumor regression, stability and rejection, to infer rigorous statistical analysis. We first confirmed that CT26 tumors grow equally well in RAG2 -/-(RAG) or WT animals, and further evidenced that TxT performed 7-8 weeks before tumor implantation neither facilitated nor impaired tumor growth ( Fig.   4A ). Depletion of Treg in DEREG mice 12-13 days post CT26 implantation induces either full rejection in all animals, or prevents tumor growth in only a fraction of mice, according to the dose (1µg twice vs 0,5µg once) of administrated DT (24, 25) . Testing the most sensitive protocols we evidenced that at least 80% of the mice fully rejected the tumor whether in the TxT or the Sham groups ( Fig. 4B) . Finally, when treating WT mice with anti-CTLA4 mAb during the first week after CT26 implantation, the majority of animals showed reduced or fully controlled tumor growth, irrespective of whether they were TxT or Sham (Fig. 4C) . Together, these data establish that antitumor immunity is not compromised in thymectomized animals.
Interruption of thymic activity potentiates immunotherapy of tumors expressing either weak or strong neoantigens.
We next tested whether tumor intrinsic immunogenicity conditions the impact of TxT on immune surveillance. The B16F10 melanoma (here after B16) expresses several neo-antigens but remains poorly immunogenic (26) unless Treg are strongly depleted from tumor implantation on (27) . The engineered B16-cOVA expresses in addition the poorly immunogenic GFP protein and the cytoplasmic portion of ovalbumin which serves as a proxy of a strong immunogenic tumor neo-antigen (Fig. S3 ). The growth of B16-cOVA but not of B16 was equally impaired or delayed in syngeneic (C57Bl/6) TxT or Sham mice, as compared to alymphoid RAG animals ( Fig. 5A) .
We tested DT effect 13 days post-B16 tumor cells implantation into DEREG mice. In this setting, most Sham mice (76%) presented tumor growth curves similar to those of WT control animals, despite DT treatment. In contrast, a sizeable fraction of TxT hosts (70%) exerted a robust control of tumor growth upon DT treatment, resulting in higher survival (70 versus 30%) and higher iTCI scores, when compared to Sham animals ( Fig. 5B) . revealed a 2 fold higher frequency of CD8 cells producing IFN-g, a parameter inversely correlated with tumor weight, and lower ratio of Treg to CD8 IFN-g producers, a hallmark of productive antitumor immunity, in TxT when compared to Sham animals (Fig. 5C) . Other cellular features included increased number of activated CD4 or CD8 cells and increased frequency of highly cycling and KLRG1 + terminally differentiated Treg in TxT vs Sham mice (Fig. S4) . Similar enhanced control of tumor growth was revealed when testing mice carrying the DTR gene inserted at the Foxp3 locus (DTR mice). In DTR, contrarily to DEREG animals, all Treg are equally targeted upon DT administration. In this model, the vast majority of mice (96%) responded to DT treatment by arrest or regression of tumor growth, and TxT animals performed better for the latter, resulting in higher iTCI scores (Fig. 5D) .
We next confirmed that anti-CTLA4 therapy fails to alter B16 tumor growth (22) and evidenced this feature is not altered in TxT mice (Fig. S5) . Surprisingly, the B16-cOVA which we showed above is spontaneously immunogenic in Sham mice did not respond to the therapy. In contrast, 60% of the animals in the TxT group, compared to 20% in the Sham cohort, controlled tumor growth for at least 20 days, maintaining a tumor size lower than the threshold of precision for measurement. Analysis of tumor growth curves evidenced a striking bimodal iTCI score distribution in TxT mice (Fig. 5E) , not related to specific experimental groups. Cellular analysis of B16-cOVA TILs confirmed a reduced ratio of Treg to CD8 IFN-g producers in TxT when compared to Sham treated animals (Fig. 5F ), in this case seemingly the result of decreased frequency of Treg (Fig. S6) . We conclude that continuous activity of the thymus is not required for a positive outcome of anti-CTLA therapy and may actually be unfavorable. Together, these data confirm that adult thymectomy does not prevent tumor immune surveillance, even if induced and irrespectively of the tumor intrinsic immunogenicity, and reveals it may improve Treg based therapy.
Discussion
In this work we document that cessation of thymic activity in adult alters Treg composition and function in the periphery. We demonstrate, across tumor models and mouse strains, that adult thymectomy per se does not provide for weaker antitumor immunity in mice and may actually favor the outcome of immunotherapies. To our knowledge, our work is the first to address experimentally the contribution of the thymus on tumor growth in otherwise healthy adults.
Together, our findings point to a scenario in which abrogation of thymic activities affects preferentially the regulatory over the ridding arm of the immune activities elicited by tumors.
To address the impact of thymic activity decline on immune regulation, we chose adult thymectomy as a study model rather than aged animals. This strategy allows to dissociate aging of the peripheral T cell pool per se from other indirect effects driven by systemic aging. For instance, other subset of immune cells, including dendritic cells that are mandatory partners of T cells, do lose competences with age (28), and senescence-associated secretory phenotype (SASP) factors produced by multiple aged-tissues have systemic and pleiotropic effects. Full ablation of the thymus after production of a normal initial T cell pool is nowadays rarely performed and limited to sporadic cases of adults with myasthenia gravis and to newborn/children presenting congenital heart defects (partial or total ablation of the thymus eases the surgical access to the heart). Follow-up of these children reveals reduced naïve T cells number and TCR diversity, but not impaired immune responses to common infections and most vaccines (29) . While these cohorts are small, and the follow-up time is in the range of one or two decades, it is noticeable that increased tumor incidence has not been reported.
Thymic output in mice has been studied in details, notably through the analysis of animals bearing the GFP gene inserted at the RAG locus, where GFP expression in the periphery reports T cells that recently exited the thymus. These studies established that full maturation of RTE is achieved in about 3 weeks (30) which certifies absence of RTE in our experimental animals 6-8 weeks post
TxT. Kinetic analysis also established that decline in RTE number starts soon after birth and reaches its maximum by 30 weeks of age (31) . At the age we analyzed mice (12-17 weeks) RTE represents about 20% of T cells corresponding to 3-4x10 6 cells/spleen (31) , ensuring our Sham controls had an active thymus. These analyses were performed in B6 animals, and it is possible that BALB/c mice have different kinetics of RTE decline. It is also possible that the cervical thymi reported in BALB/c (32) , while atrophic at steady state, compensated for, and mitigated the effect of, thoracic thymus ablation.
Our detailed cellular analysis confirms our prediction that adult thymectomy alters both Tconv and Treg composition, to somewhat similar extent, and imposes a similar bias for activated/effector/memory phenotype in the peripheral T cell pool. Our results also confirms that absence of tTreg output is not compensated by differentiation of pTreg in the periphery, as was predicted by the earlier finding that RTE are the precursors of bona fide Treg differentiated in the periphery (7, 8) . This finding is also consistent with the compromised return to homeostasis upon Treg perturbation, which we document in TxT animals. Together, these evidences support our original proposition that predicting the impact of thymic cessation on the outcome of an immune response, and even more so for a composite of self-and nonself-antigens as for a tumor, is nontrivial.
By testing tumor cell lines of distinct origins, presenting different degree of immunogenicity, and two strains of mice, we evidence that cessation of thymic activity for 2 months does not reduce (33) and the higher the efficacy in Treg killing the better the therapeutic outcomes (34) . Despite clear improvement in survival rate, some patients do not respond to such therapies and others fail to achieve a complete response; a variation not yet understood. A striking feature of our data is actually the heterogeneity of tumor growth kinetics in a single experimental group, observed only in situation of spontaneous or induced immunogenicity, and despite the experimental paradigm of tumor cell lines and isogenic mice to reduce biological variation. It would appear that interindividual variation in such restricted setting remains to be formally addressed before one could approach the full complexity of human heterogeneity.
Studies and reviews addressing the impact of thymic involution or ablation on health still reduce T cells to a pool of effector cells and appear oblivious to more than two decades of evidences that Foxp3 + Treg are essential to ensure "dominant" tolerance. In contrast, Treg-based therapies are in the clinic or being developed to the benefit of autoimmunity and cancer (9, 35) . In agreement with the notion that thymic senescence affects Treg are the epidemiological evidence that while most autoimmune diseases first manifest in children and young adults, a second wave of incidence is noticeable in older individual, when thymic activities have significantly declined.
Moreover, TxT NOD mice developed diabetes strikingly faster than Sham controls (36) , and corticosteroid treatment which induces thymocytes death further enhances the effects of cyclophosphamide-induced Treg depletion (37) . Together our analysis points to a scenario by which reduction in thymic output, be it the result of surgical ablation, stress induced contraction or age-related involution has a dual effect altering not only effector but also Treg (see Figure 6 ). As each cell compartment encompasses a very large repertoire of different TCR sequences, although larger for effector cells than for Treg, the reservoir of reactivities in each compartment is mildly affected by interrupted thymic output. In situation of sustained cessation of thymic output, the reduction in the TCR repertoire of both effector and Treg cells affects the domain of competences of each cell subset (ridding and regulation, respectively) which in most cases results in unperturbed interactions between these two compartments, and thus preserves tolerance to self-tissues and tumors. Upon added stress on the Treg compartment, such as during immune check-point inhibitor therapy, the inability of the thymus to replenish this cell pool results in unbalanced immune responses, including enhanced anti-tumor immunity. This model highlights the robustness of the immune system, explains the overall efficient immune responses (29) and mild increase in auto-reactive Ab (38) presented by humans submitted to surgical thymectomy, and argues that higher incidence of tumors with age cannot be solely attributed to thymic output decline. Further refinement of this minutes after which a Percol gradient (Sigma) was used to isolate lymphocytes. Live cells were counted using magnetic beads and Propidium Iodide. To stimulate the production of cytokines, cells were incubated for 4h at 37ºC in RPMI 1640 (Life Technologies) containing PMA (phorbol 12-myristate-13-acetate) (Sigma), Ionomycin (Sigma) and protein transport inhibitor (Brefeldin A) (eBioscience). After pre-incubation with Fc-block, surface markers were stained using antibodies described in table S1. Cells were then incubated overnight at 4ºC in Foxp3 fix/permeabilization buffer (eBioscience) and stained for intracellular transcription factors and cytokines using antibodies also described in table S1. For analysis of GFP expressing cells in DEREG animals, the GFP signal was enhanced by using anti-GFP antibody staining. Analysis was performed using Cyan ADP or BD Fortessa X20. Data were analyzed with Flowjo. Total Naive Activated Total Naive Activated Frequency of total, BAC-GFP + and BAC-GFP -Foxp3 + CD4 cells in peripheral blood samples from DT treated DEREG mice. Two groups of mice (n=4 each) were followed on alternate days post-DT injection. One representative of three independent experiments. Red frames indicate the days selected in Fig. 3 B, C for lymphoid organs analysis. C) GFP conversion experiment. hCD2 + GFP -CD4 cells were isolated from pooled spleen and lymph node of B6 CD45.1 huCD2 DEREG mice and transferred into B6 CD45.2 DEREG recipients. Donors were treated with DT 5 days earlier, recipients 1 day earlier and at the day of transfer. Analysis of donor and recipient Foxp3 + cells was performed 1 week post-transfer. Shown are a representative flow cytometry plot, used to infer the frequency of BAC expressors GFP + Treg from each origin, as well as the frequency of CD25 + cells in BAC-GFP + and BAC-GFP -Treg. One experiment (n=5). D) Foxp3 conversion experiment. CD45.1 + CD4 + CD8 -Foxp3thymocytes isolated from B6 CD45.1 huCD2 DEREG donors were transferred into B6 CD45.2 DEREG recipients that were treated with DT 1 days earlier and at the day of transfer. Analysis of donor cells was performed 1 week post-transfer. Shown is representative flow cytometry analysis, the percentages of Foxp3 + (pTreg) inside CD45.1 + CD4 donor cells, and the frequency of BAC-GFP expressors inside newly differentiated pTreg. One experiment (n=4). Statistical analysis was performed using nonparametric Mann Whitney T-test. *P < 0.05, **P < 0.005. Figure S5 
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